Available online on www.ijppr.com

International Journal of Pharmacognosy and Phytochemical Research 2023; 15(2); 38-43

eISSN: 0975-4873, pISSN: 2961-6069

Review Article

Unravelling the Complexities of Heart Failure Insights into Etiology, Pathophysiology Diagnosis and Management Approaches

Jay Prakash Yadav[1] , Riyaz Ahmad Bhat[2], Brajesh Yadav[3], Hanumanthrao C Patil[4], Rajesh Kumari Patil[5*]

[1,2,3]Pharm.D (Student), Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda
[4]Professor& Principal, Department of Pharmacy Practice, Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda
[5]Professor and HOD, Department of Pharmacy Practice, Adesh Institute of Pharmacy and Biomedical Sciences, Adesh University, Bathinda

Received:30th March 23; Revised: 20th April 23; Accepted:24th May 23; Available Online:25th June 23

ABSTRACT

Despite advances in medicine, treating heart failure (HF), which typically manifests as a disease syndrome, has been difficult for medical professionals. This is demonstrated by the substantially greater readmission rate, as well as the elevated mortality and morbidity linked to HF. In this review article, we first give a broad overview of the various heart failure pathogenesis types and diagnostic characteristics of HF the effectiveness of therapeutic approaches, and the morbidity and mortality of HF. An ageing population and an increase in multimorbidity have led to an increase in polypharmacy and heart failure. According to national and international recommendations that predispose individuals to polypharmacy, treating heart failure demands the prescription of many drugs. This review's objectives are to determine how polypharmacy has been defined among heart failure patients in the literature, determine whether a common definition in relation to heart failure can be found, and describe the prevalence. In this review we also discuss the Pathophysiological differences between HFpEF and HFrEF.

Keywords: Heart failure, etiology pathophysiology, diagnosis and management, polypharmacy, diagnosis.

INTRODUCTION

Heart failure is a state of heart disease in which, regardless of sufficient ventricular filling, the cardiac output is reduced or in which the heart is unable to pump blood at a rate sufficient to meet the tissues' needs while function parameters remain within normal limits.[5] According to the European Society of Cardiology, heart failure is a clinical syndrome with typical symptoms (such as dyspnea, ankle swelling, and fatigue) and signs (such as elevated jugular venous pressure, pulmonary crackles, and peripheral oedema) brought on by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. Only when symptoms are visible can heart failure be diagnosed. For a heart failure diagnosis, it is critical to show that there is an underlying cardiac malfunction. Systolic and/or diastolic ventricular dysfunction is frequently the result of a cardiac abnormality (such as a myocardial infarction). Heart failure may also be brought on by abnormalities in the pericardium, endocardium, heart rhythm, heart conduction, valves (stenosis, regurgitation), pericardium, or a combination of these. The pathophysiological mechanism that causes heart failure must be identified in order to select the best therapeutic choices, such as valve repair, rhythm problem treatment, or pharmaceutical treatment.[1] Heart failure, which affects 26 million people globally and causes more than one million hospital admissions each year in the USA and Europe, is becoming more and more recognised as a major public health issue on a global scale. Heart failure is quite common, and it has a significant clinical, financial, and social impact on people and health institutions.[2] There is currently a lot of proof that the severity of left ventricular dysfunction is not directly correlated with the clinical stage of persistent congestive heart failure. Numerous studies have shown that peripheral changes, such as lower

**Author for Correspondence: rkpatil3014@gmail.com*

peripheral perfusion, significantly affect the functional state and exercise capacity of individuals with chronic heart failure. Early anaerobic metabolism in skeletal muscle appears in patients with chronic heart failure compared to normal persons at the same workload. Patients with persistent heart failure show signs of weakened muscle. Vasodilators, however, do not immediately raise exercise capacity or peak oxygen demand; instead, they increase cardiac output during exercise. The oxygen utilisation is not immediately increased even when the oxygen transport to skeletal muscle is boosted by pharmacological intervention. These discoveries have given rise to the concept that skeletal muscle intrinsic defects that manifest in chronic heart failure. Recent nuclear magnetic resonance (NMR) investigations employing Even without reduced flow or in the presence of ischemia circumstances, spectroscopy has shown aberrant skeletal muscle metabolism during exercise. Recently, skeletal muscle biopsies from a small number of heterogeneous patient populations have been used to more directly address this issue. These biopsies have produced a variety of different and, at times, contradicting abnormalities. We conducted exercise testing and an in-depth ultrastructural investigation on a sizable patient population with chronic heart failure of varying functional impairments in order to establish the prevalence and characteristics of skeletal muscle abnormalities and their relation to exercise ability[3]The relationship between depression and anxiety disorders and the onset and progression of HF, as well as higher death rates, is probably mediated by both physiological and behavioural mechanisms. It can be difficult to correctly diagnose depression or anxiety disorders in HF patients due to the overlap between cardiac and mental symptoms. But the best course of action in the evaluation process is to follow the official diagnostic criteria and make use of a clinical interview. The effectiveness of medication and psychotherapy in HF patients is only partially supported by the available research. Selected serotonin reuptake medications, however, seem safe in this group of patients with HF, and cognitive behavioural therapy has been proven to enhance mental health outcomes in HF patients.[4] The cause of dilated cardiomyopathy (DCM) is unknown or uncertain in the majority of individuals. A family condition affects more than 20% of patients. Clinically, it doesn't seem possible to tell this apart from the nonfamilial variant. At least some DCM patients have been shown to have anti-myosin antibodies while others have beta-receptor antibodies, some of which may be physiologically active and have beta-agonist properties. Patients with DCM exhibit significantly higher levels of immunoreactive staining to the inducible form of nitric oxide synthase (iNOS) in cardiac myocytes and to tumour necrosis factor alpha (TNF) in vascular endothelium and smooth muscle cells than do control subjects or patients with ischemic HF.

Etiology of Heart Failure

HF can be brought on by a variety of systemic disorders, genetic abnormalities, and cardiac problems. Mixed aetiologies are possible in HF patients and are not mutually exclusive, and aetiologies differ significantly across high-income and developing nations. The worldwide burden of Sickness Study showed that there are 17 key aetiologies for HF. Four underlying diseases, including ischemic coronary artery disease, chronic obstructive pulmonary disease, antihypertensive heart disease, and rheumatic heart disorder, account for more than two thirds of all instances of HF. Despite the fact that the Global Burden of Disease Study tries to roughly estimate the burden of right-sided HF from chronic obstructive pulmonary disease, studies evaluating the prevalence of right-sided HF are scarce and need additional investigation. When compared to low-income locations, which are principally impacted by hypertensive heart disease, rheumatic heart disease, cardiomyopathy, and myocarditis, high-income regions are disproportionately affected by ischemic heart disease and chronic obstructive pulmonary disease. Policies must be tailored to population-specific risks and underlying aetiologies in order to assess and manage cardiovascular risk globally.[7]

Pathophysiology of Ischemic and Nonischemic HF

In ischemic heart disease (IHD), three processes can take place: acute, reversible ischemia; myocardial infarction (MI), which kills a discrete mass of myocytes; chronic myocardial dysfunction, which includes hibernation and stunning; and, possibly, progression to diffuse cardiac myocyte death. The cause of dilated cardiomyopathy (DCM) is unknown or uncertain in the majority of individuals. A family condition affects more than 20% of patients. Clinically, it doesn't seem possible to tell this apart from the nonfamilial variant. At least some DCM patients have been shown to have anti-myosin antibodies while others have beta-receptor antibodies, some of which may be physiologically active and have beta-agonist properties. Patients with DCM exhibit significantly higher levels of immunoreactive staining to the inducible form of nitric oxide synthase (iNOS) in cardiac myocytes and to tumour necrosis factor alpha (TNF) in vascular endothelium and smooth muscle cells than do control subjects or patients with ischemic Hf. An inflammatory response (provoked by an autoimmune or infectious event) in DCM patients may increase

TNF production, induce iNOS, and raise NO levels. NO has a detrimental inotropic effect on cardiac myocytes, and at high concentrations, it can have cytotoxic effects, most likely through the production of free radicals.[6]

Diagnosis of HF

Blood tests, such as complete blood counts, urinalyses, complete metabolic profiles for levels of serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, glucose, fasting lipid profiles, liver function tests, and thyroid-stimulating hormone are all used in the evaluation for HF. Physical examinations are also used to determine the presence of clinical symptoms and signs. The brain natriuretic peptide (BNP), which has a 70% sensitivity and 99% specificity, and N-terminal proBNP (NT-proBNP), which has a 99% sensitivity and 85% specificity, are additional HF-specific laboratory tests that have been recommended for both outpatient and hospital settings.[8] BNP is a neuro-hormone that is the activated form of proBNP, a 108-amino-acid polypeptide precursor that is kept in secretory granule form in the atria and ventricles, respectively. ProBNP is produced into ventricles in response to pressure overload and volume expansion. There, it is cleaved into the 76-peptide NT-proBNP and the 32-peptide BNP, which are both physiologically active hormones. Clinically significant as both diagnostic and prognostic markers are NT-proBNP and BNP. BNP readings greater than 500 pg/mL have an 81% positive predictive value (PPV), while values less than 100 pg/mL had a 90% negative predictive value (NPV) for the diagnosis of HF in patients presenting with acute dyspnea.[9] In individuals with a history of heart failure or cardiac dysfunction, the BNP level is a reliable indicator of the risk of death and cardiovascular events. It is important to keep in mind that while obese and overweight people have generally lower BNP levels, elevated BNP levels have also been linked to chronic hypoxia, pulmonary hypertension, renal failure, and pulmonary embolism. Additionally, other from NT-proBNP's longer half-life, there is no clinically meaningful difference between BNP and NT-proBNP in terms of diagnostic and prognostic values.

Biomarkers give light on the severity of ongoing disease in addition to offering important information on the biology of the disease. A biomarker in HF should ideally allow clinicians to: (i) identify potential underlying (and potentially treatable) causes of HF; (ii) confirm the presence or absence of the HF syndrome; and (iii) estimate the severity of HF and the risk of disease progression, according to the National Academy of Clinical Biochemistry's consensus document. Myocyte stretch biomarkers, myocyte necrosis biomarkers, systemic inflammation biomarkers, oxidative stress biomarkers, extracellular matrix turnover biomarkers, neuro-hormone biomarkers, and biomarkers of extra-cardiac processes, such as renal function, are just a few of the different biomarkers that have been categorised based on their putative functional impact on cardiac myocytes and the resulting pathophysiological changes in patients with HF.Chest X-rays, transthoracic echocardiography (TTE), computerised tomography (CT) scans, and magnetic resonance imaging (MRI) are further HF diagnostic procedures. Chest X-rays are helpful in determining the size of the heart, pulmonary congestion, and to look for other cardio-pulmonary disorders that might be causing or exacerbating the patient's symptoms. Patients presenting with HF are advised to undergo a "two-dimensional echocardiogram with Doppler" as part of their first examination. TTE is helpful in evaluating the size, thickness, motility, and valve function of the ventricles. TTE also aids in determining the heart's ejection fraction, which aids in choosing the best course of treatment.[10]

Management: Current Therapies for Heart Failure

Pharmacological Therapy

Utilising RAAS and SNS inhibitors and diuretics to achieve and maintain euvolaemia to reduce symptoms are the major goals of specific pharmacological therapy for heart failure. These goals are intended to improve prognosis and symptom statu**s.** It has been discovered that aetiology and advancement of the heart failure disease process, as well as decreased survival, are related to activation of the RAAS and SNS.[11,12] The treatment of heart failure has been transformed by blocking these systems. The cornerstone of medication therapy for systolic (i.e., low ejection fraction) heart failure is angiotensin-converting enzyme (ACE) inhibitors and beta-blockers (or angiotensin receptor blockers [ARBs] in individuals unable to tolerate ACE inhibitors). According to recommendations, these medications should be started at low dosages and increased to the target or maximum tolerated dose. Blood pressure (lying and standing), heart rate, renal function, and potassium levels should all be periodically checked for both drug groups. Due to the modest but possible risk of bilateral renal artery stenosis, careful and early monitoring of renal function is essential in patients using ACE inhibitors for the first time, especially in those with a history of hypertension. Administration of ACE inhibitors (and ARBs) in this clinical setting may result in acute renal failure. Blockers each have unique side effects.[13]

Some medications, including carvedilol and nebivolol, also have the ability to dilate blood

vessels, making them theoritically more challenging to administer to patients with borderline blood pressure levels.

However, even with a baseline systolic blood pressure cut-off of 85 mmHg, carvedilol was very well tolerated in investigations of individuals with severe heart failure [14]. Vasodilation, on the other hand, may counteract the tendency for heart failure to deteriorate too quickly. In the presence of concurrent chronic obstructive pulmonary disease (COPD), highly selective 1-blocking medications (such as nebivolol and bisoprolol) may be recommended. As long as there is no clinically substantial reversible airflow obstruction, COPD is not an absolute contraindication to blocker medication in heart failure. The use of pre- and post-bronchodilator spirometry during lung function testing makes it simple to identify this. All degrees of systolic heart failure have been demonstrated to benefit from aldosterone receptor antagonists in addition to background ACE inhibitor and beta-blocker medication. people who received the treatment right away after suffering a myocardial infarction,18 people with In individuals with advanced symptoms and those with mild systolic heart failure symptoms, respectively. Because of this, the most recent Australian guideline update1 advised adding aldosterone receptor antagonists to background ACE inhibitor and beta-blocker therapy in all patients with systolic chronic heart failure who continue to experience symptoms despite receiving these medications. Patients should be closely monitored for these side effects, especially when starting aldosterone-blocking therapy in patients with borderline hypotension, renal impairment, or diabetes mellitus, as combining RAAS blockers puts patients at increased risk of hyperkalaemia, hypotension, and renal impairment. HFPEF, however, has not yet shown any benefit from either RAAS blockers or SNS blockage. Most commonly, diuretics are used to reduce symptoms by achieving and maintaining euvolaemia. They have not been demonstrated to have prognostic value. Digoxin is the go-to treatment for people with heart failure and atrial fibrillation to modulate ventricular response. Since the publication of the Digitalis Investigation Group (DIG) study, which found no overall prognostic effect, its use in sinus rhythm has decreased. Further examination of the DIG trial, however, revealed that patients who received relatively low doses of the drug within the serum digoxin range of 0.5-0.8 ng/mL had increased survival, however this survival advantage was mostly restricted to males. Since many years ago, nitrates and hydralazine have been utilised as an ACE inhibitor substitute.

However, because this pharmacological class has been demonstrated to be advantageous, ARBs are chosen in patients who are intolerant to ACE inhibitors. Amiodarone is frequently prescribed to people who have cardiac failure and arrhythmias, however it has been discovered that it does not have any particular prognostic benefits in these patients; as a result, its usage is restricted to treating the underlying arrhythmia. It is debatable whether or not antiplatelet and anticoagulant medication should be used in heart failure. Aspirin and other antiplatelet medications ought to be continued for people with known ischemic heart disease. Warfarin should only be used in individuals with chronic heart failure and atrial fibrillation; yet, due to worries about an elevated risk of thrombosis, it is frequently recommended (without supporting data) to patients who have a noticeable dilatation of their left atrium and/or ventricle.[15]

Polypharmacy in Heart Failure Role

Polypharmacy, or the use of numerous drugs by one person, is an increasingly widespread phenomenon. Although there is no single definition of polypharmacy, it is sometimes referred to be the use of five or more medications each day. The ageing of the population and the epidemic of multimorbidity, or the prevalence of many illnesses, have been major factors in the rise of polypharmacy. Globally, polypharmacy is generally on the rise. In situations where the use of medicines has been optimised and prescriptions are made in accordance with the best available evidence, polypharmacy can either be appropriate—as when drugs are prescribed for complex conditions like heart failure or for multiple conditions—or problematic—as when drugs are prescribed inappropriately or when the intended benefits from the drugs are not realised. This situation, however, is not constant; with time, modifications to a patient's clinical situation and personal circumstances may alter the appropriateness of previously wise prescribing choices. Heart failure, like polypharmacy, is made worse in the ageing population since it is typically a long-term effect of complex interrelated comorbidity. Complex pharmaceutical regimens are used to treat and manage several of these comorbidities, including diabetes and coronary heart disease. Pharmacological treatments are mostly used to successfully treat heart failure itself. Angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), and sodium-glucose co-transporter-2 inhibitors (SGLT2) are among the medications with prognostic benefit in heart failure with ejection fraction (HFrEF).As a result of the

development of this evidence base in the 1990s and its application through national and international guidelines, heart failure patients' survival rates have increased, predisposing them to appropriate polypharmacy even before taking into account treatment for coexisting conditions. These factors are known to cause the overall pill burden and complexity of the polypharmacy to rise over time in heart failure patients. However, polypharmacy may also provide unwelcome risks to patient safety and is linked to a higher frequency of negative outcomes, such as mortality, falls, adverse medication reactions, an extended hospital stay, and readmission to the hospital soon after release. A review of polypharmacy in older patients found that adverse medication reactions were the main reason for hospitalisation in 90% of these patients, as well as an increase in drug-related issues such hospitalisation, death, and drug-drug interactions. The same review discovered that polypharmacy also contributed to a drop in physical activity, cognitive function, and drug adherence.[2]

CONCLUSION

Because of the changing age demographics and rise in obesity in western nations, the prevalence of HFpEF is reaching pandemic levels. There is currently no known effective treatment for HFpEF. The complexity of the pathophysiology of HFpEF, where restrictions in ventricular diastolic, systolic, and chronotropic reserve interact with abnormalities in the periphery, including the vasculature, endothelium, autonomic nervous system, and skeletal muscle, is largely responsible for this lack of therapeutic options. We won't see changes in the prognosis for this prevalent and developing form of heart disease without thorough phenotyping of patient-specific limits and additional investigation into the processes behind combined cardiac and vascular reserve failure. Heart failure is a complex illness that has historically contributed significantly to morbidity and mortality in both developing and industrialised nations. Early on in HF, a standardised medicinal therapy has been effective. e prevalence of polypharmacy is very high among those with heart failure. Despite the fact that the majority of research defines polypharmacy as taking more than five drugs, a single definition was not discovered. A global definition of polypharmacy is required so that it may be quantified across different cohorts. Uncertainty persists regarding the suitability of using an arbitrary cut-off for medication numbers as a definition as opposed to medication appropriateness

REFERENCES

1. Schwinger, R. H. Pathophysiology of heart failure. Cardiovascular diagnosis and therapy, 2021;11(1), 263.
2. Beezer, J., Al Hatrushi, M., Husband, A., Kurdi, A., & Forsyth, P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart failure reviews, 2022; 27(2), 465-492.
3. Drexler, H., Riede, U., Münzel, T., König, H., Funke, E., & Just, H. Alterations of skeletal muscle in chronic heart failure. Circulation, 1992; 85(5), 1751-1759.
4. Celano, C. M., Villegas, A. C., Albanese, A. M., Gaggin, H. K., & Huffman, J. C. Depression and anxiety in heart failure: a review. Harvard review of psychiatry, 2018; 26(4), 175.
5. (Denolin, H., Kuhn, H., Krayenbuehl, H., Loogen, F., & Reale, A. The defintion of heart failure. European heart journal, 1983;4(7), 445-448.
6. Follath, F., Cleland, J. G., Klein, W., & Murphy, R. Etiology and response to drug treatment in heart failure. Journal of the American College of Cardiology, 1998;32(5), 1167-1172.
7. Ziaeian, B., &Fonarow, G. C. Epidemiology and aetiology of heart failure. Nature Reviews Cardiology, 2016;13(6), 368-378.
8. Ohtani, T., Mohammed, S. F., Yamamoto, K., Dunlay, S. M., Weston, S. A., Sakata, Y., & Redfield, M. M. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. European heart journal, 2012; 33(14), 1742-1749.
9. Maries, L., & Manitiu, I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovascular journal of Africa, 2013; 24(7), 286-289.
10. Inamdar, A. A., & Inamdar, A. C. Heart failure: diagnosis, management and utilization. Journal of clinical medicine, 2016; 5(7), 62.
11. Johnston, C. I., Fabris, B., & Yoshida, K. The cardiac renin-angiotensin system in heart failure. American Heart Journal, 1993; 126(3), 756-760.
12. Parati, G., &Esler, M. The human sympathetic nervous system: its relevance in hypertension and heart failure. European heart journal, 2012; 33(9), 1058-1066.
13. Dobre, D., Haaijer-Ruskamp, F. M., Voors, A. A., & van Veldhuisen, D. J. β-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and

tolerability. Drugs & aging, 2007; 24, 1031-1044.
14. Packer, M., Coats, A. J., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P. & DeMets, D. L. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine, 2001; 344(22), 1651-1658.
15. Krum, H., & Driscoll, A. Management of heart failure. 2013.